Jiang C, Talbot D, Carazo S, Schnitzer M
Stat Med. 2025; 44(5):e70025.
PMID: 39985144
PMC: 11845851.
DOI: 10.1002/sim.70025.
Tan S, Rodriguez-Barraquer I, Kwan A, Blumberg S, Park H, Hutchinson J
Nat Commun. 2025; 16(1):1090.
PMID: 39881133
PMC: 11779853.
DOI: 10.1038/s41467-024-55029-9.
Qasmieh S, Ferdinands J, Chung J, Wiegand R, Flannery B, Rane M
medRxiv. 2025; .
PMID: 39802800
PMC: 11722453.
DOI: 10.1101/2024.12.30.24319700.
Aglipay M, Maguire J, Swayze S, Tuite A, Mamdani M, Keown-Stoneman C
Open Forum Infect Dis. 2025; 12(1):ofae718.
PMID: 39758749
PMC: 11697100.
DOI: 10.1093/ofid/ofae718.
Martinez-Baz I, Navascues A, Trobajo-Sanmartin C, Pozo F, Fernandez-Huerta M, Olazabal-Arruiz M
Int J Infect Dis. 2024; 151:107364.
PMID: 39694231
PMC: 11735411.
DOI: 10.1016/j.ijid.2024.107364.
Effectiveness of the influenza vaccine for preventing laboratory-confirmed influenza infections in outpatient immunocompromised adults, 2017-2018.
Hughes Kramer K, Zimmerman R, Haggerty C, Balasubramani G, Nowalk M, Martin E
Hum Vaccin Immunother. 2024; 20(1):2354013.
PMID: 39693194
PMC: 11188783.
DOI: 10.1080/21645515.2024.2354013.
Uncertainty in COVID-19 transmission could undermine our ability to predict long COVID.
Beams A, Earn D, Colijn C
J R Soc Interface. 2024; 21(221):20240438.
PMID: 39657791
PMC: 11631421.
DOI: 10.1098/rsif.2024.0438.
Bias and negative values of COVID-19 vaccine effectiveness estimates from a test-negative design without controlling for prior SARS-CoV-2 infection.
Wiegand R, Fireman B, Najdowski M, Tenforde M, Link-Gelles R, Ferdinands J
Nat Commun. 2024; 15(1):10062.
PMID: 39567531
PMC: 11579392.
DOI: 10.1038/s41467-024-54404-w.
Double Negative Control Inference in Test-Negative Design Studies of Vaccine Effectiveness.
Li K, Shi X, Miao W, Tchetgen Tchetgen E
J Am Stat Assoc. 2024; 119(547):1859-1870.
PMID: 39524693
PMC: 11545655.
DOI: 10.1080/01621459.2023.2220935.
Influenza Vaccine Effectiveness and Progress Towards a Universal Influenza Vaccine.
Cowling B, Okoli G
Drugs. 2024; 84(9):1013-1023.
PMID: 39167316
PMC: 11438668.
DOI: 10.1007/s40265-024-02083-8.
Potential biases in test-negative design studies of COVID-19 vaccine effectiveness arising from the inclusion of asymptomatic individuals.
Ortiz-Brizuela E, Carabali M, Jiang C, Merckx J, Talbot D, Schnitzer M
Am J Epidemiol. 2024; 194(3):844-856.
PMID: 39160637
PMC: 11879563.
DOI: 10.1093/aje/kwae288.
Hypothesis testing and sample size considerations for the test-negative design.
Huo Y, Yang Y, Halloran M, Longini Jr I, Dean N
BMC Med Res Methodol. 2024; 24(1):151.
PMID: 39014324
PMC: 11251325.
DOI: 10.1186/s12874-024-02277-4.
Pneumococcal vaccination effectiveness (PCV13 and PPSV23) in individuals with and without reduced kidney function: a test-negative design study.
Le D, Chang A, Grams M, Coresh J, Ishigami J
Clin Kidney J. 2024; 17(6):sfae145.
PMID: 38915439
PMC: 11194481.
DOI: 10.1093/ckj/sfae145.
Prior infections and effectiveness of SARS-CoV-2 vaccine in test-negative studies: a systematic review and meta-analysis.
Tsang T, Sullivan S, Huang X, Wang C, Wang Y, Nealon J
Am J Epidemiol. 2024; 193(12):1868-1881.
PMID: 38904437
PMC: 11637527.
DOI: 10.1093/aje/kwae142.
Effectiveness of mass dengue vaccination with CYD-TDV (Dengvaxia®) in the state of Paraná, Brazil: integrating case-cohort and case-control designs.
Diaz-Quijano F, de Carvalho D, Raboni S, Shimakura S, Maron de Mello A, da Costa-Ribeiro M
Lancet Reg Health Am. 2024; 35:100777.
PMID: 38807985
PMC: 11131085.
DOI: 10.1016/j.lana.2024.100777.
End of 2022/23 Season Influenza Vaccine Effectiveness in Primary Care in Great Britain.
Whitaker H, Willam N, Cottrell S, Goudie R, Andrews N, Evans J
Influenza Other Respir Viruses. 2024; 18(5):e13295.
PMID: 38744684
PMC: 11093773.
DOI: 10.1111/irv.13295.
Relative Vaccine Effectiveness of Cell- vs Egg-Based Quadrivalent Influenza Vaccine Against Test-Confirmed Influenza Over 3 Seasons Between 2017 and 2020 in the United States.
Stein A, Mills C, McGovern I, McDermott K, Dean A, Bogdanov A
Open Forum Infect Dis. 2024; 11(5):ofae175.
PMID: 38698895
PMC: 11064727.
DOI: 10.1093/ofid/ofae175.
Opportunities and challenges for T cell-based influenza vaccines.
Mosmann T, McMichael A, LeVert A, McCauley J, Almond J
Nat Rev Immunol. 2024; 24(10):736-752.
PMID: 38698082
DOI: 10.1038/s41577-024-01030-8.
Reduced Effectiveness of Repeat Influenza Vaccination: Distinguishing Among Within-Season Waning, Recent Clinical Infection, and Subclinical Infection.
Bi Q, Dickerman B, Nguyen H, Martin E, Gaglani M, Wernli K
J Infect Dis. 2024; 230(6):1309-1318.
PMID: 38687898
PMC: 11646584.
DOI: 10.1093/infdis/jiae220.
Identifying and characterizing high-risk populations in pilot malaria elimination districts in Madagascar: a mixed-methods study.
Gebreegziabher E, Raoliarison A, Ramananjato A, Fanomezana A, Rafaliarisoa M, Ralisata S
Malar J. 2024; 23(1):121.
PMID: 38664837
PMC: 11046788.
DOI: 10.1186/s12936-024-04927-w.